14th Mar 2025 7:00 am |
RNS |
Private Placing and Conversion of CLNs |
10th Mar 2025 7:30 am |
RNS |
Board Changes |
10th Mar 2025 7:00 am |
RNS |
Proposed Sale of Oncogeni Ltd |
4th Mar 2025 7:00 am |
RNS |
Update on Sale of Lyramid |
4th Feb 2025 10:58 am |
RNS |
Director/PDMR Shareholding |
3rd Feb 2025 7:00 am |
RNS |
Share Purchase Agreement Signed - Sale of Lyramid |
2nd Jan 2025 7:00 am |
RNS |
Proposed Sale of Midkine Portfolio |
4th Dec 2024 4:00 pm |
RNS |
Director Share Distribution |
7th Nov 2024 7:00 am |
RNS |
Conversion of Convertible Loan Notes |
27th Sep 2024 7:00 am |
RNS |
Interim Results to 30 June 2024 |
23rd Sep 2024 7:00 am |
RNS |
Grant of Japan MK Cell Patent |
19th Sep 2024 7:00 am |
RNS |
STAT-6 siRNA Demonstrates Efficacy in Immunology |
2nd Sep 2024 7:00 am |
RNS |
Grant of MK Cell Patent & Licencing Update |
27th Jun 2024 12:46 pm |
RNS |
Results of AGM |
20th Jun 2024 7:00 am |
RNS |
Appointment of Broker |
4th Jun 2024 7:00 am |
RNS |
Notice of Annual General Meeting |
23rd May 2024 7:05 am |
RNS |
Issue of Convertible Loan Notes & Board Changes |
23rd May 2024 7:00 am |
RNS |
Midkine Antibody Licencing Deal |
26th Apr 2024 7:00 am |
RNS |
Annual Report & Financial Statements - 31 Dec 2023 |
5th Apr 2024 7:00 am |
RNS |
Response to Share Price Movement |
11th Mar 2024 7:00 am |
RNS |
Positive Results: Midkine mRNA and STAT-6 siRNA |
6th Feb 2024 7:00 am |
RNS |
Operations Update |
24th Nov 2023 7:00 am |
RNS |
Change of Auditor |
6th Nov 2023 7:00 am |
RNS |
Significant Mesodermal Killer Cell Milestone |
27th Sep 2023 7:00 am |
RNS |
Interim Results to 30 June 2023 |
22nd Sep 2023 11:42 am |
RNS |
Investor Presentation via Investor Meet Company |
14th Aug 2023 7:00 am |
RNS |
Expansion of Patent Portfolio |
7th Aug 2023 7:00 am |
RNS |
Development of New Novel siRNA Therapeutics |
2nd Aug 2023 7:00 am |
RNS |
Director/PDMR Shareholding |
12th Jul 2023 10:27 am |
RNS |
Director/PDMR Shareholding |
29th Jun 2023 10:05 am |
RNS |
Results of AGM |
29th Jun 2023 7:00 am |
RNS |
AGM Statement |
27th Jun 2023 7:00 am |
RNS |
Investor Presentation via Investor Meet Company |
26th Jun 2023 2:41 pm |
RNS |
Director/PDMR Shareholding |
26th Jun 2023 10:36 am |
RNS |
Director/PDMR Shareholding |
26th Jun 2023 10:00 am |
RNS |
Director/PDMR Shareholding |
22nd Jun 2023 7:00 am |
RNS |
RNA Medicine Shows In Vitro Anti-Cancer Efficacy |
19th Jun 2023 7:00 am |
RNS |
Antibody Program Results & Orphan Drug Indication |
13th Jun 2023 7:00 am |
RNS |
Anti-Cancer MDK mRNA - Positive in vitro Results |
7th Jun 2023 10:11 am |
RNS |
Restoration of Trading |